Evoluer30-30 msds.pdf

MATERIAL SAFETY DATA SHEET
SECTION 1: PRODUCT AND COMPANY IDENTIFICATION
PRODUCT NAME: Evoluer 30-30 ULV
EPA REG. NUMBER:
769-983
PRODUCT NUMBER: 51030, 51031, 51032, 51033, 51034
MANUFACTURER: Value Garden Supply
ADDRESS: P.O. Box 585, St. Joseph, MO 64502
WEBSITE: www.allprovector.com
MANUFACTURER PHONE: (888) 603-1008
MANUFACTURER FAX PHONE: (952) 884-6149
EMERGENCY PHONE: (800) 858-7378
PRODUCT USE: For effective control of Adult Mosquitoes. For application by Public Health Officials and Trained
Personnel of Mosquito Abatement Districts and Other Mosquito Control Programs.
SECTION 2: COMPOSITION/INFORMATION ON INGREDIENTS
INGREDIENTS*: CAS NO. % WT OSHA TWA OSHA STEL ACGIH TWA ACGIH STEL
Permethrin:
8042-47-50 <40.% 5mg/M3 N/A 5mg/M3 10mg/M3 * All ingredients in quantities > 1.0 % (0.1 % for carcinogens or teratogens) that are potentially hazardous per OSHA
definitions
N/A = not applicable NE = not established SECTION 3: HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW: Potential Health Effects
POTENTIAL HEALTH EFFECTS: Eye and skin contact, inhalation. Prolonged or frequent repeated skin contact with
permethrin may cause allergic reaction in some individuals. Repeated and prolonged skin contact with piperonyl butoxide
may cause skin irritation. This product may cause temporary eye irritation.
SYMPTOMS OF ACUTE EXPOSURE: Large, toxic doses of permethrin, administered to laboratory animals, have
produced central nervous system effects with symptoms that include diarrhea, salivation, bloody nose, tremors and
intermittent convulsions. Overexposure to permethrin via inhalation also produced hyperactivity and hypersensitivity.
CARCINOGENICITY: Permethrin: A statistically significant increase of lung and liver tumors was observed in female mice
receiving diets containing 375 and 750 mg/Kg/day over 85 weeks. Piperonyl Butoxide: Marginally higher incidences of
benign liver tumors in mice were observed following lifetime high dose exposures. The significance of this observation is
questionable and under review. The doses at which tumors were observed greatly exceeded human dietary intake. At
anticipated dietary exposure levels, it is highly unlikely that piperonyl butoxide would result in carcinogenic effects. IARC
has also concluded that there is no evidence for the carcinogenicity of white oils when administered by routes other than
by interperitoneal injection. The solvent is not carcinogenic according to the OSHA Hazard Communication Standard.
SECTION 4: FIRST AID MEASURES
EYES: Immediately flush eyes with large amounts of water and continue flushing until irritation subsides. If irritation
persists, seek medical attention (based on solvent).
SKIN: Take off contaminated clothing. Rinse skin immediately with plenty of water for 15 to 20 minutes. Call a Poison
Control Center for treatment advice.
INGESTION: Immediately call a physician or Poison Control Center or doctor. Do not induce vomiting unless told by a
poison control center or a doctor. Do not give any liquid to the person. Do not give anything by mouth to an unconscious
person.
MATERIAL SAFETY DATA SHEET
INHALATION: The solvent in this product has a low vapor pressure and is not expected to present an inhalation exposure
hazard during mixing and loading. Follow directions for use on product packaging when applying this product.
NOTE TO PHYSICIAN: Contains petroleum distillate – vomiting may cause aspiration hazard
SECTION 5: FIRE-FIGHTING MEASURES
FLAMMABILITY CLASSIFICATION: Non-flammable Liquid
FLASH POINT: 200°F
AUTOIGNITION TEMPERATURE: NE
EXTINGUISHING MEDIA: Use water fog, dry chemical, foam or CO2 extinguishing media.
SPECIAL FIRE FIGHTING PROCEDURES: Wear full protective clothing and self-contained breathing apparatus.
Evacuate nonessential personnel from the area to prevent human exposure to fire, smoke, fumes or products of
combustion. Prevent use of contaminated buildings, area
and equipment until decontaminated. Use as little water as possible to prevent spread of contaminated
runoff.
UNUSUAL FIRE AND EXPLOSION HAZARDS:
NFPA HAZARD CLASSIFICATION: HEALTH FIRE REACTIVITY SPECIFIC
Non-fire
NFPA HAZARD RATING CODES: INSIGNIFICANT
SECTION 6: ACCIDENTAL RELEASE MEASURES
STEPS TO BE TAKEN IN CASE MATERIAL IS RELEASED OR SPILLED: Wear chemical safety glasses with side
shields or chemical goggles, rubber gloves, rubber boots, long-sleeved shirt, long pants, to prevent contact with spilled
material. For small spills, cover the spill with an absorbent material such as pet litter. Sweep up and place in an approved
chemical container. Wash the spill area with water containing a strong detergent, absorb with pet litter or other absorbent
material, sweep up and place in a chemical container. Seal the container and handle in an approved manner. Flush the
area with water to remove any residue. Do not allow wash water to contaminate water supplies.
SECTION 7: HANDLING AND STORAGE
HANDLING AND STORAGE: Store the material in a well-ventilated, secure area, out of the reach of children and
domestic animals. Do not store food, beverages or tobacco products in the storage area. Prevent eating, drinking, tobacco
usage, and cosmetic application in areas where there is a potential for exposure to the material. Always wash thoroughly
after handling.
SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION
The employee must wear protective clothing and related safety equipment. Good ventilation should be sufficient for mostconditions. Positive pressure self contained breathing apparatus should be used for confined spaces and high exposureoperations. The employee should shower at the end of the workday. The employee must wear clean clothes every day orafter a spill if the clothes become contaminated. Always wash hands and face with soap and water prior to eating,drinking, smoking or using toilet facilities. It is best not to wear contact lenses but use safety prescription glasses.
SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES
APPEARANCE: Clear Amber
VAPOR PRESSURE (mmHg): Solvent - <1 mm Hg @ 70°F
ODOR: Slight solvent and licorice
MATERIAL SAFETY DATA SHEET
PHYSICAL STATE: Liquid
SPECIFIC GRAVITY: 0.8530
BOILING POINT: NE
PERCENT VOLATILE BY VOLUME: Solvent 39%
MELTING POINT: N/A
VISCOSITY: 600 cps
FREEZING POINT: N/A
AUTO IGNITION: N/A
WATER SOLUBILITY: Oil Solution will not mix in water
OTHER SOLUBILITIES: NE
SECTION 10: STABILITY AND REACTIVITY
STABILITY: Stable
INCOMPATIBILITY (MATERIAL TO AVOID): Flame, heat, ignition sources and strong oxidizers or reducing agents.
HAZARDOUS POLYMERIZATION: Will not occur.
SECTION 11: TOXICOLOGICAL INFORMATION
ACUTE ORAL EFFECTS: Oral LD50 (Rat): >500 to <5,000 mg./Kg. (female) >5,000 mg./Kg. (male)
ACUTE DERMAL EFFECTS: Dermal LD50 (Rat): >2,000 mg/Kg.
CARCINOGENICITY: Permethrin: A statistically significant increase of lung and liver tumors was observed in female mice
receiving diets containing 375 and 750 mg/Kg/day over 85 weeks. Piperonyl Butoxide: Marginally higher incidences of
benign liver tumors in mice were observed following lifetime high dose exposures. The significance of this observation is
questionable and under review. The doses at which tumors were observed greatly exceeded human dietary intake. At
anticipated dietary exposure levels, it is highly unlikely that piperonyl butoxide would result in carcinogenic effects. IARC
has also concluded that there is no evidence for the carcinogenicity of white oils when administered by routes other than
by interperitoneal injection. The solvent is not carcinogenic according to the OSHA Hazard Communication Standard.
EYE EFFECTS: Minimally irritating
INHALATION: 4-hour LC50 (Rat): >2.02 mg./L.
SKIN CONTACT: Non-irritating.
SKIN SENSITIZE: Permethrin is a skin sensitizer in some individuals.
MUTAGENIC POTENTIAL: Permethrin and Piperonyl Butoxide did not produce any mutagenic effects when tested in the
Ames test.
REPRODUCTIVE HAZARD POTENTIAL: Permethrin and Piperonyl Butoxide were not teratogenic when tested in rats.
HAZARDOUS DECOMPOSITION PRODUCTS: Carbon monoxide and/or carbon dioxide. Chlorine and hydrogen chloride
may be formed.
SECTION 12: ECOLOGICAL INFORMATION
Permethrin and piperonyl butoxide are highly toxic to fish and other aquatic organisms. Do not apply directly to water, orto areas where surface water is present or to intertidal areas below the mean high water mark other than as instructed onthe product label. Do not contaminate water by disposing of equipment washwater. Apply this product only as specified onthe label.
SECTION 13: DISPOSAL CONSIDERATIONS
WASTE DISPOSAL METHOD: Do not reuse product containers. Dispose of product containers, waste containers, and
residues according to Federal, State and local health and environmental regulations.
MATERIAL SAFETY DATA SHEET
SECTION 14: TRANSPORT INFORMATION
*DOT HAZARD DESCRIPTION: Not Regulated
SECTION 15: REGULATORY INFORMATION
SARA TITLE III CLASSIFICATION:
Section 311/312: Acute Health Hazard – Yes
Chronic Health Hazard – Yes
Fire Hazard – No
Sudden release of pressure hazard – No
Reactivity hazard – No
Section 313 chemicals:
Permethrin (30%) (CAS # 52645-53-1)
Piperonyl Butoxide (30%) (CAS # 51-03-6)
TSCA STATUS: Exempt from TSCA
This product contains a toxic chemical or chemicals subject to the reporting requirements of
Section 313 of Title III and of 40 CFR 372. Any copies or redistribution of this MSDS must
include this notice.

INDIVIDUAL STATES: N/A
SECTION 16: OTHER INFORMATION
This information is provided in good faith, but without express or implied warranty. For additional information, refer to theAmerican Conference of Governmental Industrial Hygienists (ACGIH) documentation of TLV's (Threshold Limit Values) forindividual components and the DOT Emergency Response Guidebook.

Source: http://www.co.beaufort.sc.us/departments/Public-Safety/mosquito-control/documents/evoluer-30-30-msds-latest.pdf

Microsoft word - die bluthirnschranke.doc

Appendix Die Blut-Hirn-Schranke von Edwin H. Bessai - Die Blut-Hirn-Schranke der Gehirnkapillaren. Prodrugs, das Prodrug „Levodopa“ und „Levodopa-Präparate“ Warum die Ernährung bei der Einnahme von Levodopa-Präparaten eine Rolle spielt, wie deshalb die Ernährung gestaltet werden muss und wie Levodopa-Präparate eingenommen werden müssen. Das Gehirn mu

Untitled

January 2008 Ontario Drug Benefit (ODB) stops paying for over 30 antibiotic generic products Ever since the introduction of Ontario’s Transparent Drug System for Patients Act, 2006, the landscape continues to change, creating a 2-tier system between the private and public sector. Increases in the prices of generics, combined with off-loading expenses to private payors and pla

Copyright ©2010-2018 Medical Science